top pick in health sector, page-13

the CEO has told another poster by phone ;

He expressed that he was very aware of managing shareholders expectations around this date and that this the expected September announcement factors a margin of error in the scenario that CE mark was delayed for whatever reason (which was my primary concern - too often CEOs and BODs are all too enthusiastic about promising the world to the SHs which only results in expectations not being met and the SP getting pummelled). I stress again that he could articulate enough how extremely positive he felt that he would be making a positive announcement in September regarding CE Mark.

He also stressed that the current cash position provided the company with ample funds to see the through to Q1 2017 as such there would be no need for a capital raising in the near future (he alluded to late 2016 post CE mark and FDA approval). He said that their only costs were salary and wages, and that CE mark has been paid for in full and further research and development has been postponed till after CE mark as the primary goal of the company is in obtaining a license so as to be able to generate revenues.